Surprisingly, the use of IMS with an anti-EpCAM antibody and ICC with anti-cytokeratin antibodies for detection of tumour cells resulted in minimal detection overlap, although results obtained with each method were associated with outcome in distinct prognostic subgroups of CRC patients. Here, EPCAM is linked to neoplasm.